By working literally around the clock, a sizeable team of scientists out of Stanford Medicine (Stanford University) have developed a compelling test to detect antibodies against SARS-CoV-2 in blood samples. This is in contrast to the existing diagnostic tests used for COVID-19, which detect genetic material from the virus in respiratory secretions. Rather, this test probes for antibodies to the virus in plasma, the liquid in blood as a means to generate data about an individual’s immune response to an infection. This represents a breakthrough as this kind of test will be required for opening up the U.S. to business as usual as the pandemic is contained.
TrialSite News provides the Q&A breakdown of this great news for the TrialSite Network.
Why is this a significant breakthrough?
First an early scientific report published in JAMA suggests that convalescent plasma—collected from the blood of people recovering from the disease and containing anti-SARS-CoV-2 antibodies—could help treat people with acute COVID-19. If these results are true in larger studies, serology testing, such as the one the Stanford test makes possible, will be a strategic approach for identifying peo...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).